BD Biosciences to Expand Manufacturing in Durham, North Carolina
News May 14, 2007
BD Biosciences, a segment of BD (Becton, Dickinson and Company), has announced plans to expand its Treyburn facility in Durham, North Carolina to consolidate and increase U.S. manufacturing capacity for its Discovery Labware products, including BD Falcon™ products.
The $25 million capital investment project is expected to create 28 new positions in 2007 and a total of 100 by the end of 2008, building on a presence of approximately 285 employees today.
With expertise in fluid handling, tissue culture, and cell screening, BD Biosciences - Discovery Labware provides products and services with applications for drug discovery, high throughput screening, angiogenesis and tumor invasion.
The new capacity is intended to meet growing demand for BD Falcon™ tubes, pipettes, plates, cell inserts, and other products used in life science research settings. Approximately 50,000 square feet of manufacturing space will be added, directly contiguous to existing production lines.
“Treyburn offers an ideal platform as BD looks to increase capacity to meet demand for our Discovery Labware products,” said Todd Shackett, Plant Manager of the Treyburn facility. “We are able to build upon our own successful manufacturing operations, as well as the pool of high-tech expertise in this region. We couldn’t be more pleased to be growing in Durham. Today’s moves will provide the cornerstone for future development.”
Bill Kozy, Executive Vice President, added: “This expansion will allow BD to meet growing demand for class-leading products that are critical tools for life science researchers everywhere, while also enabling us to optimize our global production and supply chains for related products.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018